Rochester

Monro, Inc. To Present At The Oppenheimer 20th Annual Consumer Growth Virtual Conference

Wednesday, June 3, 2020 - 12:30pm

ROCHESTER, N.Y., June 03, 2020 (GLOBE NEWSWIRE) -- Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive undercar repair and tire services, today announced that Brett Ponton, President and Chief Executive Officer, and Brian DAmbrosia, Executive Vice President and Chief Financial Officer, will present at the Oppenheimer 20th Annual Consumer Growth Virtual Conference.

Key Points: 
  • ROCHESTER, N.Y., June 03, 2020 (GLOBE NEWSWIRE) -- Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive undercar repair and tire services, today announced that Brett Ponton, President and Chief Executive Officer, and Brian DAmbrosia, Executive Vice President and Chief Financial Officer, will present at the Oppenheimer 20th Annual Consumer Growth Virtual Conference.
  • The Companys presentation is scheduled for Tuesday, June 16, 2020 at 2:45 PM ET.
  • A live webcast of the virtual event will be available via the Investors section of the Companys corporate website ( corporate.monro.com ) and will be archived for at least two weeks.
  • The Company has experienced significant growth in recent years through acquisitions and, to a lesser extent, the opening of newly constructed stores.

OptimizeRx to Present at William Blair & Company's 40th Annual Growth Stock Conference, June 9-11, 2020

Friday, May 29, 2020 - 1:31pm

ROCHESTER, Mich., May 29, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, payers and providers, has been invited to present in William Blair & Companys 40th Annual Growth Stock Conference being held June 9-11, 2020.

Key Points: 
  • ROCHESTER, Mich., May 29, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, payers and providers, has been invited to present in William Blair & Companys 40th Annual Growth Stock Conference being held June 9-11, 2020.
  • The event is for institutional clients of William Blair and is by invitation only.
  • To schedule a one-on-one meeting with OptimizeRx, please contact your William Blair institutional sales representative.
  • As an independent and employee-owned firm, together with its strategic partners, William Blair operates in more than 20 offices worldwide.

Vyriad Inc. to Present Clinical Trial Updates for its Oncolytic Virotherapies at Virtual 2020 ASCO Annual Meeting

Friday, May 29, 2020 - 12:30pm

ROCHESTER, Minn., May 29, 2020 (GLOBE NEWSWIRE) -- Vyriad, Inc. announced today that it will present data and information about the design of clinical trials evaluating its oncolytic viruses at the 2020 American Society of Clinical Oncology (ASCO) annual meeting, a virtual event that will be held May 29-June 2.

Key Points: 
  • ROCHESTER, Minn., May 29, 2020 (GLOBE NEWSWIRE) -- Vyriad, Inc. announced today that it will present data and information about the design of clinical trials evaluating its oncolytic viruses at the 2020 American Society of Clinical Oncology (ASCO) annual meeting, a virtual event that will be held May 29-June 2.
  • Vyriad will present three posters: one focusing on infusion duration and the recommended regimen of intravenous Voyager-V1, an investigational vesicular stomatitis virus programmed to target, infect and kill cancer cells.
  • Vyriad and Regeneron have entered into an exclusive strategic agreement to develop the Voyager-V1 and other vesicular stomatitis virus-based therapies.
  • Ph 2 trial of Voyager-V1 (vesicular stomatitis virus expressing human IFN and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma

Monro, Inc. Announces Fourth Quarter and Fiscal 2020 Financial Results

Thursday, May 28, 2020 - 12:30pm

Sales for the fourth quarter of the fiscal year ended March 28, 2020 (fiscal 2020) decreased 0.4% to $286.1 million, as compared to $287.2 million for the fourth quarter of the fiscal year ended March 30, 2019 (fiscal 2019).

Key Points: 
  • Sales for the fourth quarter of the fiscal year ended March 28, 2020 (fiscal 2020) decreased 0.4% to $286.1 million, as compared to $287.2 million for the fourth quarter of the fiscal year ended March 30, 2019 (fiscal 2019).
  • Interest expense was $7.1 million for the fourth quarter of fiscal 2020, as compared to $6.8 million for the fourth quarter of fiscal 2019.
  • Diluted loss per share for the fourth quarter of fiscal 2020 was $.12, compared to diluted earnings per share of $.50 in the fourth quarter of fiscal 2019.
  • During the fourth quarter of fiscal 2020, the Company opened three company-operated stores and closed nine company-operated stores, ending the quarter with 1,283 company-operated stores and 98 franchised locations.

OptimizeRx to Present at RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020

Monday, May 18, 2020 - 9:01pm

ROCHESTER, Mich., May 18, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, payers and providers, has been invited to present in RBC Capital Markets virtual Global Healthcare Conference: "Beyond 2020: The Changing Face of Healthcare.

Key Points: 
  • ROCHESTER, Mich., May 18, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, payers and providers, has been invited to present in RBC Capital Markets virtual Global Healthcare Conference: "Beyond 2020: The Changing Face of Healthcare.
  • OptimizeRx CEO William Febbo is scheduled to present on May 19, 2020, at 8:35 a.m. Eastern time, as well as participate in virtual one-on-one meetings.
  • For any questions about OptimizeRx, contact Ron Both of CMA at (949) 432-7557 or submit your request here .
  • OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that facilitates communication at point-of-care among all stakeholders in healthcare.

Washington Companies Cited for Workplace Safety

Friday, May 15, 2020 - 2:20pm

LAS VEGAS, NV, May 15, 2020 - (ACN Newswire) - Washington State Department of Labor and Industries, Division of Occupation Safety and Health has cited the Washington Companies' Modern Machinery site in Rochester, WA for violation of State Statute WAC 296-800-11005.

Key Points: 
  • LAS VEGAS, NV, May 15, 2020 - (ACN Newswire) - Washington State Department of Labor and Industries, Division of Occupation Safety and Health has cited the Washington Companies' Modern Machinery site in Rochester, WA for violation of State Statute WAC 296-800-11005.
  • The contention in an ongoing federal lawsuit is that Washington Companies failed to provide fall protection to the commercial truck drivers on the Washington Companies site, thus depriving a driver from complying with the State of Washington statutes regarding working height.
  • Washington Companies lack of fall protection for the driver required the driver to rely on a Washington Companies employee to provide loaded height dimensions of loads loaded at Washington Companies' Modern Machinery site in Rochester, WA.
  • Modern Machinery is a part of a large consortium of privately held companies collectively known as the Washington Companies, owned by billionaire Dennis R. Washington.

Monro, Inc. to Report Fourth Quarter and Fiscal 2020 Earnings on May 28, 2020

Friday, May 15, 2020 - 12:30pm

ROCHESTER, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive undercar repair and tire services, will release fiscal 2020 fourth quarter and full-year earnings on May 28, 2020.

Key Points: 
  • ROCHESTER, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive undercar repair and tire services, will release fiscal 2020 fourth quarter and full-year earnings on May 28, 2020.
  • The Company will host a conference call and audio webcast on Thursday, May 28, 2020 at 8:30 a.m. Eastern Time.
  • The conference call may be accessed by dialing 1-877-425-9470 and using the required passcode 13704065.
  • The Company went public in 1991 and trades on The Nasdaq Stock Market under the symbol MNRO.

Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update

Thursday, May 14, 2020 - 1:45pm

ROCHESTER, N.Y., May 14, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntingtons disease, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.

Key Points: 
  • ROCHESTER, N.Y., May 14, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntingtons disease, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.
  • Raised gross proceeds of approximately $7.5 million through a private placement of 1,468,563 shares of the companys common stock in January 2020.
  • The companys ongoing CLASSICAL-Lung study is evaluating pepinemab in combination with avelumab for the treatment of advanced (stage IIIB/IV) NSCLC.
  • Vaccinex has been invited to present near topline data at the virtual ASCO conference in late May 2020.

Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting

Wednesday, May 13, 2020 - 10:02pm

It is a multi-center, open-label study designed to evaluate the safety and potential efficacy of the combination of pepinemab and avelumab in subjects with advanced NSCLC.

Key Points: 
  • It is a multi-center, open-label study designed to evaluate the safety and potential efficacy of the combination of pepinemab and avelumab in subjects with advanced NSCLC.
  • The combination of pepinemab and avelumab has been demonstrated to be well-tolerated at all dose levels tested.
  • Beyond neurology, Vaccinex has determined that, in combination with checkpoint inhibitors, pepinemab has potential to increase objective responses in oncology.
  • Vaccinex is focused on the development of pepinemab for the treatment of cancer and neurodegenerative diseases including Huntingtons disease.

OptimizeRx Empowers Patients and Providers with Telemedicine Tools Tailored for Women’s Health

Wednesday, May 13, 2020 - 3:00pm

Our RMDY digital health tools enable Dr. Bitner and other healthcare providers to have touchpoints with their patients throughout the year, increasing adherence and creating better outcomes.

Key Points: 
  • Our RMDY digital health tools enable Dr. Bitner and other healthcare providers to have touchpoints with their patients throughout the year, increasing adherence and creating better outcomes.
  • OptimizeRxs RMDY digital health tools are proven to drive positive, measurable behavior change across a variety of health management programs by helping patients efficiently track and manage their habits with the goal of improving personal health.
  • The solution is part of OptimizeRxs comprehensive digital health program designed for providers, health plans, life science companies and other healthcare organizations.
  • The clinic specializes in womens health with an expertise in midlife, menopause, and sexual health.